trimethyloxamine has been researched along with Recrudescence in 3 studies
trimethyloxamine: used in manufacture of quaternary ammonium cpds; insect attractant; warming agent for gas; oxidant; structure
trimethylamine N-oxide : A tertiary amine oxide resulting from the oxidation of the amino group of trimethylamine.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Gencer, B | 1 |
| Li, XS | 2 |
| Gurmu, Y | 1 |
| Bonaca, MP | 1 |
| Morrow, DA | 1 |
| Cohen, M | 1 |
| Bhatt, DL | 1 |
| Steg, PG | 1 |
| Storey, RF | 1 |
| Johanson, P | 1 |
| Wang, Z | 2 |
| Hazen, SL | 2 |
| Sabatine, MS | 1 |
| Haghikia, A | 2 |
| Liman, TG | 1 |
| Bledau, N | 1 |
| Schmidt, D | 1 |
| Zimmermann, F | 1 |
| Kränkel, N | 1 |
| Widera, C | 1 |
| Sonnenschein, K | 1 |
| Weissenborn, K | 1 |
| Fraccarollo, D | 1 |
| Heimesaat, MM | 1 |
| Bauersachs, J | 1 |
| Zhu, W | 1 |
| Bavendiek, U | 1 |
| Endres, M | 1 |
| Landmesser, U | 1 |
| Al-Ani, B | 1 |
| Fitzpatrick, M | 1 |
| Al-Nuaimi, H | 1 |
| Coughlan, AM | 1 |
| Hickey, FB | 1 |
| Pusey, CD | 1 |
| Savage, C | 1 |
| Benton, CM | 1 |
| O'Brien, EC | 1 |
| O'Toole, D | 1 |
| Mok, KH | 1 |
| Young, SP | 1 |
| Little, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
3 other studies available for trimethyloxamine and Recrudescence
| Article | Year |
|---|---|
Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial.
Topics: Aged; Aspirin; Bacteria; Case-Control Studies; Dual Anti-Platelet Therapy; Female; Gastrointestinal | 2020 |
Gut Microbiota-Dependent Trimethylamine N-Oxide Predicts Risk of Cardiovascular Events in Patients With Stroke and Is Related to Proinflammatory Monocytes.
Topics: Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Brain Ischemia; Cardiovascular Disea | 2018 |
Changes in urinary metabolomic profile during relapsing renal vasculitis.
Topics: Animals; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Citric Acid; Disease Models, An | 2016 |